［1］中国成人血脂异常防治指南制定联合委员会.中国成人血脂异常防治指南［J］.中华心血管病杂志，2007，35：390-410.

［2］Stone NJ，Robinson J，Lichtenstein AH，et al.2013ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults：a report of the American College of Cardiology/ American Heart Association task force on practice guidelines［J］.J Am Coll Cardiol，2014，63（25Pt B）：2889-2934.

［3］Scandinavian simvastatin survival study group.Randomised trial of lowering in 4444patients with coronary heart disease：the Scandinavian simvastatin survival study（4S）［J］.Lancet，1994，344：1383-1389.

［4］Sharp collaborative group.Study of heart and renal protection （SHARP）：randomized trial to assess the effects of lowering lowdensity lipoprotein cholesterol among 9438patients with chronic kidney disease ［J］.Am Heart J，2010，160：785-794.e10.

［5］Baigent C，Blackwell L，Emberson J，et al.Efficacy and safety of more intensive lowering of LDL cholesterol：a meta-analysis of data from 170000 participants in 26randomised trials［J］.Lancet，2010，376：1670-1681.

［6］FDA Drug Safety Communication：New restrictions，contraindications，and dose limitations for Zocor（simvastain）to reduce the risk of muscle injury［EB/OL］.（2011-060-08）［2014-03-27］.http：∥www.fda.gov/ Drugs/DrugSafety/ucm256581.htm

［7］The National Lipid Association recommendations for patientcentered treatment of dyslipidemia［EB/OL］.（2014-05-20）［2014-05-21］.https：∥www.lipid.org/nla/recommendations-patient-centered-management-dyslipidemia.

［8］Cannon CP，Braunwald E，McCabe CH，et al.Intensive versus moderate lipid lowering with statins after acute coronary syndromes［J］.N Engl J Med，2004，350：1495-1504.

［9］HPS2-THRIVE Collaborative Group.HPS2-THRIVE randomized placebo-controlled trial in 25 673high-risk patients of ER niacin/laropiprant：trial design，pre-specified muscle and liver outcomes，and reasons for stopping study treatment［J］.Eur Heart J，2013，34：1279-1291.